Evaluation of bleeding status and complications in patients with desmopressin prophylaxis before renal biopsy

In this study, 677 patients who underwent kidney biopsy between 2013 and 2023 at Trakya University Faculty of Medicine, Department of Internal Medicine, Department of Nephrology were evaluated by dividing them into two groups (those receiving and not receiving desmopressin). When the demographic data of the patients included in the study, who received desmopressin, were examined, it was determined that BMI was low, mean blood pressure and mean age were high, comorbidities were more and male gender was dominant. When the laboratory data of the patient group receiving desmopressin were examined, anemia before biopsy, lower kidney function tests, higher amounts of proteinuria, higher erythrocyte sedimentation rate and higher MCV values ​​after biopsy; It was found to be significantly different from the group that did not receive it. It was thought that the presence of these risk factors could give insight into the possibility of bleeding after biopsy and the need for blood product replacement. Significant differences were detected when comparing hemoglobin changes after biopsy with desmopressin prophylaxis. According to the statistical results, it was revealed that bleeding could not be prevented despite prophylaxis and there was significantly more bleeding in the high-risk patient group using desmopressin. According to statistical results, it was shown that bleeding could not be prevented despite prophylaxis in the high-risk patient group using desmopressin and it was revealed that there was significantly more bleeding. When comparing eGFR values ​​with desmopressin use, statistically significant differences were detected between the groups. It has been shown that desmopressin prophylaxis is mainly applied to high-risk groups with eGFR values ​​below 30 ml/min/1.73m2 and between 30-60 ml/min/1.73m 2 . It was determined that the group not receiving desmopressin was mostly composed of patients with eGFR values higher than 60 ml/min/1.73m 2 . In our center, It was revealed that there was no need for blood product replacement in the majority of kidney biopsies performed. Patients who required the blood product replacement were in the desmopressin treated group.